| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KAL1 |
| Uniprot No | P23352 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 384-680aa |
| 氨基酸序列 | RLKSAKVSLH FTSTHATNNK EQLVKTRKGG IQTQLPFQRR RPTRPLEVGA PFYQDGQLQV KVYWKKTEDP TVNRYHVRWF PEACAHNRTT GSEASSGMTH ENYIILQDLS FSCKYKVTVQ PIRPKSHSKA EAVFFTTPPC SALKGKSHKP VGCLGEAGHV LSKVLAKPEN LSASFIVQDV NITGHFSWKM AKANLYQPMT GFQVTWAEVT TESRQNSLPN SIISQSQILP SDHYVLTVPN LRPSTLYRLE VQVLTPGGEG PATIKTFRTP ELPPSSAHRS HLKHRHPHHY KPSPERY |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于KAL1重组蛋白的3篇参考文献及摘要概括：
---
1. **文献名称**：*KAL1重组蛋白在神经轴突导向中的作用机制研究*
**作者**：Hardelin JP, et al.
**摘要**：研究通过重组KAL1蛋白体外实验，揭示其通过调控细胞外基质与FGF受体互作，促进嗅觉神经元轴突导向及迁移，为Kallmann综合征的分子机制提供依据。
---
2. **文献名称**：*重组人anosmin-1(KAL1)蛋白的表达与纯化*
**作者**：Soussi-Yanicostas N, et al.
**摘要**：报道利用哺乳动物细胞表达系统成功制备高纯度重组KAL1蛋白，并验证其生物活性，为后续功能研究奠定技术基础。
---
3. **文献名称**：*KAL1重组蛋白对肾纤维化的调控作用*
**作者**：Hu Y, et al.
**摘要**：实验发现重组KAL1蛋白通过抑制TGF-β信号通路，减轻小鼠肾脏纤维化，提示其在慢性肾病治疗中的潜在应用价值。
---
注：以上文献信息为模拟概括，实际引用需核对具体论文原文。若需真实文献，建议通过PubMed/Google Scholar以“KAL1 recombinant protein”或“anosmin-1 expression”为关键词检索。
The KAL1 gene, located on the X chromosome, encodes the extracellular matrix-associated protein anosmin-1. This glycoprotein plays a critical role in neuronal development, particularly in the migration of gonadotropin-releasing hormone (GnRH) neurons and olfactory bulb morphogenesis. Mutations in KAL1 are linked to X-linked Kallmann syndrome, a genetic disorder characterized by delayed puberty due to hypogonadotropic hypogonadism and anosmia (loss of smell).
Recombinant KAL1 protein is engineered to study the molecular mechanisms underlying these developmental processes and explore therapeutic interventions. Produced through heterologous expression systems (e.g., mammalian cells or bacteria), the purified protein retains functional domains essential for its biological activity, including a whey acidic protein (WAP) domain and fibronectin type III repeats. These structural elements facilitate interactions with fibroblast growth factor receptor 1 (FGFR1) and heparan sulfate proteoglycans, crucial for axonal guidance and cell adhesion.
Research applications include in vitro models of neuronal migration, screening for compounds that modulate anosmin-1 signaling, and potential gene therapy approaches. The recombinant protein also serves as a tool to investigate genotype-phenotype correlations in Kallmann syndrome and test hypotheses about anosmin-1's role in extracellular matrix remodeling. Current challenges involve maintaining post-translational modifications critical for function and optimizing delivery methods for therapeutic use. Studies using recombinant KAL1 have provided insights into the interplay between genetic and hormonal factors in reproductive neurology.
×
